AML
From the Journals
Hospice care underused in older patients with de novo AML
Fewer than half of older adults with AML were enrolled in hospice,
News
VSTs can treat 5 different viral infections after HSCT
New research suggests virus-specific T cells (VSTs) can protect patients from severe viral infections that sometimes occur after hematopoietic...
News
Strategy could reduce myelosuppression in AML
Researchers believe they may have found a way to prevent chemotherapy-induced myelosuppression in acute myeloid leukemia (AML). The team found...
News
Targeting heme synthesis to treat AML
Researchers have found evidence to suggest that a type of acute myeloid leukemia (AML) depends on the production of heme. The group’s work has...
News
FDA approves drug to treat 2 types of AML
The US Food and Drug Administration (FDA) has granted approval for CPX-351 (Vyxeos™), a fixed-ratio combination of cytarabine and daunorubicin...
News
Liposomal daunorubicin and cytarabine approved for t-AML, AML-MRC
Vyxeos, a liposome-encapsulated combination of daunorubicin and cytarabine, has been approved for the treatment of adults with newly-diagnosed...
News
FDA approves enasidenib to treat relapsed/refractory AML
The US Food and Drug Administration (FDA) has approved marketing of the oral IDH2 inhibitor enasidenib (IDHIFA®). The drug is now approved to...
News
Enasidenib gets FDA approval for AML with IDH2 mutations
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard...
News
FDA grants drug breakthrough designation for AML
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to venetoclax (Venclexta®). The designation is for...
News
Team makes ‘fundamental’ AML discovery
A newly identified pathway plays a “fundamental” role in acute myeloid leukemia (AML), according to researchers. The team discovered that AML...
News
Predicting response to treatment in AML, MDS
Researchers say they have determined which patients will respond to treatment with SY-1425, a retinoic acid receptor alpha (RARα) agonist. The...